Cargando…
Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
BACKGROUND: Hormone receptor and HER-2/neu discordance between the primary lesion and first metastasis has been reported. This study was performed to determine further biomarker discordance rates between the first and subsequent metastatic breast cancer lesions. METHODS: We performed a retrospective...
Autores principales: | Lower, Elyse E, Khan, Shagufta, Kennedy, Diane, Baughman, Robert P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546587/ https://www.ncbi.nlm.nih.gov/pubmed/28814897 http://dx.doi.org/10.2147/BCTT.S137709 |
Ejemplares similares
-
Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance
por: Bick, Gregory, et al.
Publicado: (2022) -
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni, Mohamad Adham, et al.
Publicado: (2021) -
Establishment and characterization of two human breast carcinoma cell lines by spontaneous immortalization: Discordance between Estrogen, Progesterone and HER2/neu receptors of breast carcinoma tissues with derived cell lines
por: Kamalidehghan, Behnam, et al.
Publicado: (2012) -
Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005) -
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
por: Gómez-Martin, Carlos, et al.
Publicado: (2012)